Compare Biogen Inc (BIIB) vs PepsiCo, Inc. (PEP) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

PepsiCo (PEP) trades at $138.22, up 0.38% on the day, with the stock showing mixed technical signals amid a bearish overall trend. The company maintains strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $2.20 beating expectations of $2.19, and robust profitability metrics including 10.78% net income margin and 51.59% ROE. Recent news highlights price adjustments for snacks and sponsorship changes, while analysts maintain a cautious but generally positive outlook.

PepsiCo presents a stable investment case with strong cash flow generation and dividend consistency, though near-term headwinds include pricing sensitivity and competitive pressures. The consensus price target of $158.79 suggests 15% upside potential, supported by ongoing business optimization efforts. Key risks include consumer pushback on pricing and execution challenges in North American markets.